Aclaris Therapeutics, Inc.
ACRS
$1.50
$0.010.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.09M | -96.55M | -7.59M | -10.99M | -16.94M |
| Total Depreciation and Amortization | 128.00K | 143.00K | 179.00K | 242.00K | 243.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.84M | 88.47M | 3.80M | 3.10M | 4.89M |
| Change in Net Operating Assets | -1.94M | -994.00K | 25.60M | -4.68M | -9.01M |
| Cash from Operations | -13.06M | -8.94M | 22.00M | -12.32M | -20.82M |
| Capital Expenditure | -43.00K | 0.00 | 0.00 | 14.00K | -135.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 19.16M | -88.72M | 2.80M | -688.00K | 16.97M |
| Cash from Investing | 19.12M | -88.72M | 2.80M | -674.00K | 16.83M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 80.00M | 32.00K | -- | -- |
| Repurchase of Common Stock | -275.00K | -333.00K | -10.00K | -11.00K | -55.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -5.09M | -- | -- | -- |
| Cash from Financing | -275.00K | 74.58M | 22.00K | -11.00K | -55.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.79M | -23.08M | 24.82M | -13.01M | -4.04M |